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Progress in human gene therapy. There have been major advances in
our understanding of the molecular biology and pathophysiology of
human disease over the past decade. This expanding knowledge of the
basic mechanisms of human disease coupled with the development of
efficient methods of transferring genes to mammalian cells has stimulated
considerable interest in treating diseases with gene therapy. Clinical trials
have demonstrated that human gene transfer is possible, that several
strategies exist for successfully introducing exogenous genes to human
cells, that a variety of transgenes can evoke biologic responses important
to human diseases, and that gene transfer can provide valuable insights
into the pathophysiology of human disorders. Initial clinical trials have
yielded encouraging results and adverse reactions have been uncommon.
Despite the advances in human gene transfer, significant obstacles need to
be overcome before it becomes a firmly established therapeutic option for
human illness. The potential benefits of utilizing human gene therapy in
the treatment of hereditary and acquired disease have generated interest
in further advancing this remarkable technology.
Gene therapy is a clinical strategy in which genetic material is
transferred to the somatic cells of an individual to correct an
inherited genetic disease or treat an acquired disorder [1—4]. The
technology to accomplish this has advanced to the clinical arena
much more rapidly than expected. There have already been
numerous human clinical trials demonstrating that it is possible to
transfer genetic material to human target cells and that proteins
coded by the newly transferred gene can exert significant biologic
effects [2, 5—7]. As more human genes are cloned and knowledge
of the molecular biology of human diseases advances, the poten-
tial applications for this remarkable technology will continue to
expand.
To carry out gene therapy, the exogenous gene(s) is transferred
in an expression cassette, including the promoter which regulates
expression of the new gene, the gene (often in the form of a
eDNA), and stop signals to terminate translation [4, 8]. The
expression cassette is transferred to target cells using a "vector."
This review will provide an overview of the strategies for human
gene transfer including the vector systems and expression cas-
settes utilized, as well as an example of the early human gene
transfer clinical trials for cystic fibrosis, and the obstacles that
need to be overcome before human gene therapy will become a
reality as a therapeutic option.
Transfer of genetic material to target cells can take place either
er viva or in vivo. Er vivo gene transfer involves introducing the
expression cassette to target cells in the laboratory [4]. The
genetically altered cells are then readministered to the recipient,
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usually after being amplified [4, 5]. In the in viva strategy, the
expression cassette is transferred directly to the cells of the
recipient [81. Both strategies employ the use of vectors which
deliver the expression cassette to the location in the target cell
where it can function appropriately [1—3, 9]. The most commonly
used vector systems include retrovirus, adenovirus, and plasmid-
liposome complexes. Each delivers the expression cassette via
distinct mechanisms and each has its own unique advantages and
disadvantages [1, 7],
Retrovirus vectors
Retroviruses contain a central core structure surrounding a
viral RNA genome [10]. Complexed to the RNA is reverse
transcriptase, a DNA polymerase which converts the RNA ge-
nome into a proviral DNA form. The proviral DNA is transported
to the cell nucleus where it is converted to a double stranded form
and randomly integrated into the genome of the host cell [10, 11].
The retroviral vectors used in gene therapy are retroviruses in
which viral genes have been removed or modified so that the
retrovirus is deficient in its ability to replicate and produce
infectious virus and no viral proteins are made in the host cell [11].
The most commonly used retrovirus vector is based upon the
Maloney murine leukemia virus rendered replication deficient by
the removal of the gag, pol, and env gene regions that encode the
structural proteins required to produce infectious virus [11]. As
the genetic material is incorporated into the genome of the
recipient, the genotype of the target cell is, in theory, permanently
modified. Replication deficient retroviral vectors in current use
require the target cells to be replicating for the new gene to be
incorporated into the target cell genome and be expressed [12].
The stable incorporation of the expression cassette into the
genome of the target cell is a potential advantage of retroviral
vectors in the treatment of hereditary and chronic disorders which
require long-term transgene expression [12]. However, stable
integration of the expression cassette carries with it the potential
risk of chronic over expression of the transgene with possible toxic
side effects. In addition, the random insertion of proviral DNA
into the host genome could potentially activate an oncogene or
disrupt a tumor suppressor gene [12—15]. Retroviral vectors are
difficult to purify or concentrate in high titers partly due to their
relative lability compared with other vector systems [13, 16].
Finally, during production of the retroviral vectors in packaging
cells (which contain the necessary genes for viral protein synthesis
and viral construction), the potential exists for genetic recombi-
nation and rearrangements altering the viral genome [14, 17].
These limitations of retroviral vector based gene transfer systems
have restricted their use almost entirely to r vivo applications [7].
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Adenovirus vectors
The adenovirus is a 36 kb double stranded DNA virus that
efficiently transfers genes in vivo to a variety of different target cell
types [18, 19]. The virus is made suitable for gene transfer by
deleting the genes in the El region required for viral replication
[20]. The expendable E3 region is often deleted to allow addi-
tional room for a larger expression cassette [21]. The resulting
replication deficient adenovirus vector can accommodate up to 7.5
kb of exogenous genetic information [2, 211. The recombinant
vector is packaged and propagated in 293 cells, a human embry-
onic kidney cell line that contains the El region in its genome and
thus is able to support El adenoviral replication [20]. The vector
can be produced to very high titers and is capable of efficiently
transferring genetic information to nonreplicating and replicating
cells [2, 15]. The newly transferred genetic information remains
epi-chromosomal, thus eliminating the risks of random insertional
mutagenesis and permanent alteration of the genotype of the
target cell [2, 15, 19]. Adenoviruses are not oncogenic in humans
[22]. For these reasons, adenovirus vectors have been used more
than any other vector for in vivo human gene therapy clinical trials
[7]. The major disadvantages of adenovirus vectors include non-
specific inflammation, specific anti-adenoviral vector cellular and
humoral immunity, and a limited duration of transgene expres-
sion, likely due to elimination of the target cell by cellular immune
mechanisms [23—28]. To obtain the persistent transgene expres-
sion required for effective treatment of chronic disorders, it will be
necessary to design the vectors such that they are not seen by the
immune system, suppress the immune system, or repeatedly
administer the adenovirus vector.
Plasmid-liposome complexes
Plasmids are genetically engineered circular double stranded
DNA molecules that can be designed to contain an expression
cassette [8]. Naked plasmids inefficiently transfer expression cas-
settes to their target cells, but by complexing the plasmid with
liposomes the efficiency of gene transfer is improved [2, 29—34].
Advantages of plasmid-liposome complex vectors include their
ability to transfer large expression cassettes and their relatively
low potential (as compared with viral vectors) to evoke immuno-
genic responses in the host. The major disadvantages of this vector
system is the low efficiency of gene transfer, requiring a large
number of plasmid-liposome complexes to be presented to the
target cell to obtain adequate gene transfer [7, 29].
Other vectors
Several other viral vectors are currently being examined as
potential vehicles for human gene transfer. The herpes simplex 1
virus has attracted attention as a possible vector for in vivo gene
therapy because of its propensity to enter a latent stage that could
potentially result in long-term transgene expression. The large
herpes viral DNA genome can accommodate expression cassettes
as large as 25 kb [15]. Adeno-associated virus (AAV) is a
parvovirus not known to cause human disease [35]. Wild-type
AAV demonstrates site-specific integration into the host genome
[36—39]. Although this has not been demonstrated with the AAV
vectors in current use, a predictable site of expression cassette
incorporation would eliminate the risks associated with random
insertion while retaining the desired characteristic of possible
long-term transgene expression [15].
Expression cassettes and the objectives of early clinical trials
A variety of promoters and transgenes have been evaluated in
human gene transfer trials [7]. Most of the expression cassettes
have utilized highly active, constitutive promoters [7]. The early
clinical trials have focused primarily on diseases with a poor
prognosis and limited therapeutic options. The human gene
transfer studies fall into two groups: marker and therapeutic [8].
Marker gene transfer studies to date have involved the transfer
of expression cassettes containing bacterial resistance genes to
target cells, thus allowing for the selection of the genetically
modified cells in the production process and in analysis of the
efficacy of gene transfer [40, 41]. As the marker genes serve no
biologic function other than to identify the cells containing the
transgene, these trials have focused on evaluating the feasibility
and safety of gene transfer, and to explore biologic mechanisms
relevant to human disease [42]. Most of the marker studies have
utilized retroviral vectors to introduce the neomycin phospho-
transferase gene or the hygromycin-resistant gene to target cells
[7]. Target cells have usually been of the hematopoietic cell
lineage and studies have mainly been conducted in patients with
malignant disorders or the acquired immunodeficiency syndrome
[7, 8].
In contrast to the marker gene transfer studies, the therapeutic
trials are designed to examine the feasibility, safety, and effective-
ness of transferring expression cassettes containing genes biolog-
ically important to treating human diseases. These studies seek to
determine the level and duration of transgene expression, the
biologic impact that the transgene product has on the disease
process in the host, and the potential for adverse effects and
immune responses to be elicited in the host.
Quite remarkably, successful human gene transfer has been
demonstrated utilizing in vivo and ex vivo strategies to deliver
marker and therapeutic genes and adenoviral and plasmid-lipo-
some complexes in in vivo strategies in a wide range of underlying
diseases [7]. Overall, the evidence is impressive and convincing,
with successful gene transfer in humans demonstrated in 28 ex vivo
and 10 in vivo studies [7]. An example of an in vivo clinical
application of human gene therapy is the in vivo, adenovirus
vector-mediated transfer of the cystic fibrosis transmembrane
conductance regulator (CFTR) gene to the respiratory epithelium
of patients with cystic fibrosis [43, 44].
Cystic fibrosis as a model for gene therapy
Cystic fibrosis (CF), an autosomal recessive disorder, is the
most common lethal hereditary disease in Caucasians (approxi-
mately 1/2500 births) [45—47]. The disease is caused by mutations
in the cystic fibrosis transmembrane conductance regulator gene
[47—50]. CFTR is a 250 kb gene segment located on chromosome
7 that encodes a cyclic-AMP regulatable chloride channel found
on the apical surface of epithelial cells [46, 48, 49, 51]. The most
common mutation causing CF is a single amino acid deletion at
position 508, present in approximately 70% of patients with CF
[45, 49, 50]. Mutations in the CFTR gene result in a deficiency in
CFTR function in airway epithelial cells, and consequent abnor-
mal electrolyte transport across the epithelial surface [46, 52—54].
The resulting pulmonary manifestations include chronic respira-
tory tract infection, chronic inflammation of the airway epithelial
surface, and an abnormal accumulation of thick purulent mucoid
secretions in the tracheobronchial tree [46, 47]. The result is
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progressive respiratory failure and death, with an average life span
of 29 years [46, 55]. Since the respiratory disease in CF results
from a defective CFTR gene and the human CFTR cDNA has
been cloned, the respiratory epithelium of patients with cystic
fibrosis would appear to be an ideal target for human gene
therapy.
The first step toward this goal was to demonstrate that a
replication deficient adenovirus carrying the normal CFTR cDNA
driven by a constitutive promoter could transfer the CFTR gene
to the respiratory epithelium in animals [43]. The CFTR gene was
expressed for at least six weeks in these experimental animals [43].
In addition, this vector containing the CFTR cDNA was shown to
be capable of correcting the chloride ion secretion in airway
epithelial cells derived from individuals with cystic fibrosis [43, 56,
57]. These encouraging preliminary studies paved the way for in
vivo human gene transfer utilizing an adenovirus vector.
On April 17, 1993, after extensive pre-clinical testing of the
vector, the first viral in vivo human gene therapy trial was initiated
when an adenoviral vector with the normal CVFR eDNA was
administered to a 23-year-old patient with cystic fibrosis [44]. The
goals of this initial human gene therapy clinical trial were to
examine the range of safe doses for delivering the vector to
respiratory epithelium, and to determine if this vector was capable
of delivering a normal CFTR gene to the airway epithelium of
these individuals, with consequent expression of the human CFTR
protein. By obtaining bronchial brushings several days after
administration of the vector to the airways, it was apparent that
the CFTR transgene was transferred and functional [44]. Because
the technology has not been available to demonstrate function of
the newly exposed CFTR protein in vivo in the airways, initial
experiments have focused on the nasal epithelium as a surrogate
site to demonstrate correction of the abnormal CFTR channel
with gene therapy [7]. Partial correction of electrolyte transport
and partial difference across the nasal epithelium after transfer of
a normal CFTR cDNA has been demonstrated in several, but not
all, studies [26, 58, 59]. These initial results are quite encouraging,
but much work needs to be done to further demonstrate and
improve the feasibility, safety, and efficacy of utilizing gene
therapy vectors to treat cystic fibrosis.
Obstacles to gene therapy
The techniques of human gene transfer and the clinical trials
exploring gene therapy vectors as therapeutics have advanced at a
remarkable pace. Research is now focusing on overcoming the
obstacles to human gene therapy becoming a therapeutic option.
The ideal gene delivery vector would efficiently and specifically
transfer the gene to target cells, and subsequently obtain high,
regulatable, and durable levels of gene expression [7]. In addition,
the vector would not evoke an immune response (unless designed
to do so), and would be non-toxic to the recipient. Furthermore,
the ideal vector would be easily purified in a high concentration
and without risks of recombination and replication. It is now
recognized that this "ideal vector" will be different for each gene
therapy application. Improving the transfer efficiency and pro-
longing the duration of transgene expression will be accomplished
through a better understanding of the mechanisms by which
vectors gain access to cells, what factors influence their access, and
what factors contribute to the loss of transgene expression. Tissue
specific and regulatable promoters will act to optimize the level
and location of transgene expression. The immune system will
likely impact the duration of expression. It may be necessary to
modulate the host immune response to optimize a particular gene
therapy strategy. This is particularly important in cases where the
gene therapy vector needs to be readministered to maintain long
term gene expression. Certainly, there are many questions that
need to be answered prior to gene therapy vectors being routinely
administered.
The accomplishments of the gene transfer technology have
been quite impressive. There has been a rapid progression of gene
transfer applications moving from the laboratory to the clinical
arena. Human gene transfer is feasible and current strategies are
safe. Transgenes can be expressed in the target cells and the
expressed proteins can elicit relevant biological responses. As
knowledge of the molecular mechanisms of disease continues to
advance, more human genes are cloned, and the gene transfer
technology progresses, the potential applications for human gene
therapy will continue to expand.
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